117 related articles for article (PubMed ID: 14516919)
1. Development of resistance to disoxaril in Coxsackie B1 virus-infected newborn mice.
Nikolova I; Galabov AS
Antiviral Res; 2003 Sep; 60(1):35-40. PubMed ID: 14516919
[TBL] [Abstract][Full Text] [Related]
2. Disoxaril mutants of Coxsackievirus B1: phenotypic characteristics and analysis of the target VP1 gene.
Nikolova I; Galabov AS; Petkova R; Chakarov S; Atanasov B
Z Naturforsch C J Biosci; 2011; 66(11-12):627-36. PubMed ID: 22351989
[TBL] [Abstract][Full Text] [Related]
3. Antiviral effect of the combination of enviroxime and disoxaril on coxsackievirus B1 infection.
Nikolaeva L; Galabov AS
Acta Virol; 2000 Apr; 44(2):73-8. PubMed ID: 10989697
[TBL] [Abstract][Full Text] [Related]
4. Antiviral activity of WIN 54954 in coxsackievirus B2 carrier state infected human myocardial fibroblasts.
Heim A; Pfetzing U; Müller G; Grumbach IM
Antiviral Res; 1998 Jan; 37(1):47-56. PubMed ID: 9497072
[TBL] [Abstract][Full Text] [Related]
5. Anti-enteroviral triple combination of viral replication inhibitors: activity against coxsackievirus B1 neuroinfection in mice.
Stoyanova A; Nikolova I; Pürstinger G; Dobrikov G; Dimitrov V; Philipov S; Galabov AS
Antivir Chem Chemother; 2015 Dec; 24(5-6):136-147. PubMed ID: 27815331
[TBL] [Abstract][Full Text] [Related]
6. Stabilization of the antigenicity of coxsackie B procapsids by disoxaril.
Frisk G; Halloran M; Didarholm H
J Virol Methods; 1993 Dec; 45(2):235-9. PubMed ID: 8113348
[TBL] [Abstract][Full Text] [Related]
7. Therapy of coxsackie virus B3-induced myocarditis with WIN 54954 in different formulations.
Pauksen K; Ilbäck NG; Friman G; Fohlman J
Scand J Infect Dis Suppl; 1993; 88():125-30. PubMed ID: 8390715
[TBL] [Abstract][Full Text] [Related]
8. Synergistic drug combinations against the in vitro replication of Coxsackie B1 virus.
Nikolaeva-Glomb L; Galabov AS
Antiviral Res; 2004 Apr; 62(1):9-19. PubMed ID: 15026197
[TBL] [Abstract][Full Text] [Related]
9. Antiviral Combination Approach as a Perspective to Combat Enterovirus Infections.
Galabov AS; Nikolova I; Vassileva-Pencheva R; Stoyanova A
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2015; 36(2):91-9. PubMed ID: 27442375
[TBL] [Abstract][Full Text] [Related]
10. Genome analysis of coxsackievirus B1 isolates during the consecutive alternating administration course of triple antiviral combination in newborn mice.
Grozdanov P; Joffret ML; Stoyanova A; Polston P; Achouri E; Nikolova I; Delpeyroux F; Galabov AS
Antivir Chem Chemother; 2020; 28():2040206620906061. PubMed ID: 32041425
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of the Consecutive Alternating Administration Course of a Triple Antiviral Combination in Coxsackievirus B3 Infections in Mice.
Vassileva-Pencheva R; Galabov AS
Drug Res (Stuttg); 2016 Dec; 66(12):639-643. PubMed ID: 27552486
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo activities of WIN 54954, a new broad-spectrum antipicornavirus drug.
Woods MG; Diana GD; Rogge MC; Otto MJ; Dutko FJ; McKinlay MA
Antimicrob Agents Chemother; 1989 Dec; 33(12):2069-74. PubMed ID: 2559655
[TBL] [Abstract][Full Text] [Related]
13. Clearance of a persistent human enterovirus infection of the mouse central nervous system by the antiviral agent disoxaril.
Jubelt B; Wilson AK; Ropka SL; Guidinger PL; McKinlay MA
J Infect Dis; 1989 May; 159(5):866-71. PubMed ID: 2540248
[TBL] [Abstract][Full Text] [Related]
14. Phyllaemblicin B inhibits Coxsackie virus B3 induced apoptosis and myocarditis.
Wang YF; Wang XY; Ren Z; Qian CW; Li YC; Kaio K; Wang QD; Zhang Y; Zheng LY; Jiang JH; Yang CR; Liu Q; Zhang YJ; Wang YF
Antiviral Res; 2009 Nov; 84(2):150-8. PubMed ID: 19699238
[TBL] [Abstract][Full Text] [Related]
15. New class of early-stage enterovirus inhibitors with a novel mechanism of action.
Ma Y; Abdelnabi R; Delang L; Froeyen M; Luyten W; Neyts J; Mirabelli C
Antiviral Res; 2017 Nov; 147():67-74. PubMed ID: 28993161
[TBL] [Abstract][Full Text] [Related]
16. WIN 54954 treatment of mice infected with a diabetogenic strain of group B coxsackievirus.
See DM; Tilles JG
Antimicrob Agents Chemother; 1993 Aug; 37(8):1593-8. PubMed ID: 8215268
[TBL] [Abstract][Full Text] [Related]
17. Susceptibility of coxsackievirus B3 laboratory strains and clinical isolates to the capsid function inhibitor pleconaril: antiviral studies with virus chimeras demonstrate the crucial role of amino acid 1092 in treatment.
Schmidtke M; Hammerschmidt E; Schüler S; Zell R; Birch-Hirschfeld E; Makarov VA; Riabova OB; Wutzler P
J Antimicrob Chemother; 2005 Oct; 56(4):648-56. PubMed ID: 16150864
[TBL] [Abstract][Full Text] [Related]
18. Attenuated virulence of pleconaril-resistant coxsackievirus B3 variants.
Groarke JM; Pevear DC
J Infect Dis; 1999 Jun; 179(6):1538-41. PubMed ID: 10228078
[TBL] [Abstract][Full Text] [Related]
19. Treatment of coxsackievirus-B3-infected BALB/c mice with the soluble coxsackie adenovirus receptor CAR4/7 aggravates cardiac injury.
Dörner A; Grunert HP; Lindig V; Chandrasekharan K; Fechner H; Knowlton KU; Isik A; Pauschinger M; Zeichhardt H; Schultheiss HP
J Mol Med (Berl); 2006 Oct; 84(10):842-51. PubMed ID: 16924471
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of poliovirus uncoating by disoxaril (WIN 51711).
Zeichhardt H; Otto MJ; McKinlay MA; Willingmann P; Habermehl KO
Virology; 1987 Sep; 160(1):281-5. PubMed ID: 2820136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
